Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 62

1.

The discovery of the benzhydroxamate MEK inhibitors CI-1040 and PD 0325901.

Barrett SD, Bridges AJ, Dudley DT, Saltiel AR, Fergus JH, Flamme CM, Delaney AM, Kaufman M, LePage S, Leopold WR, Przybranowski SA, Sebolt-Leopold J, Van Becelaere K, Doherty AM, Kennedy RM, Marston D, Howard WA Jr, Smith Y, Warmus JS, Tecle H.

Bioorg Med Chem Lett. 2008 Dec 15;18(24):6501-4. doi: 10.1016/j.bmcl.2008.10.054. Epub 2008 Oct 15.

PMID:
18952427
2.

Magnetic resonance imaging determination of tumor grade and early response to temozolomide in a genetically engineered mouse model of glioma.

McConville P, Hambardzumyan D, Moody JB, Leopold WR, Kreger AR, Woolliscroft MJ, Rehemtulla A, Ross BD, Holland EC.

Clin Cancer Res. 2007 May 15;13(10):2897-904.

3.

Dynamic imaging of emerging resistance during cancer therapy.

Lee KC, Hall DE, Hoff BA, Moffat BA, Sharma S, Chenevert TL, Meyer CR, Leopold WR, Johnson TD, Mazurchuk RV, Rehemtulla A, Ross BD.

Cancer Res. 2006 May 1;66(9):4687-92.

4.

Plasma vascular endothelial growth factor and interleukin-8 as biomarkers of antitumor efficacy of a prototypical erbB family tyrosine kinase inhibitor.

Christensen JG, Vincent PW, Klohs WD, Fry DW, Leopold WR, Elliott WL.

Mol Cancer Ther. 2005 Jun;4(6):938-47.

5.

Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts.

Fry DW, Harvey PJ, Keller PR, Elliott WL, Meade M, Trachet E, Albassam M, Zheng X, Leopold WR, Pryer NK, Toogood PL.

Mol Cancer Ther. 2004 Nov;3(11):1427-38.

6.

The influence of tumor size and environment on gene expression in commonly used human tumor lines.

Gieseg MA, Man MZ, Gorski NA, Madore SJ, Kaldjian EP, Leopold WR.

BMC Cancer. 2004 Jul 15;4:35.

7.

Radiosensitization by pan ErbB inhibitor CI-1033 in vitro and in vivo.

Nyati MK, Maheshwari D, Hanasoge S, Sreekumar A, Rynkiewicz SD, Chinnaiyan AM, Leopold WR, Ethier SP, Lawrence TS.

Clin Cancer Res. 2004 Jan 15;10(2):691-700.

8.

Radiosensitization of p53 mutant cells by PD0166285, a novel G(2) checkpoint abrogator.

Wang Y, Li J, Booher RN, Kraker A, Lawrence T, Leopold WR, Sun Y.

Cancer Res. 2001 Nov 15;61(22):8211-7.

9.

Differential utilization and localization of ErbB receptor tyrosine kinases in skin compared to normal and malignant keratinocytes.

Stoll SW, Kansra S, Peshick S, Fry DW, Leopold WR, Wiesen JF, Sibilia M, Zhang T, Werb Z, Derynck R, Wagner EF, Elder JT.

Neoplasia. 2001 Jul-Aug;3(4):339-50.

10.

Cell cycle and biochemical effects of PD 0183812. A potent inhibitor of the cyclin D-dependent kinases CDK4 and CDK6.

Fry DW, Bedford DC, Harvey PH, Fritsch A, Keller PR, Wu Z, Dobrusin E, Leopold WR, Fattaey A, Garrett MD.

J Biol Chem. 2001 May 18;276(20):16617-23. Epub 2001 Feb 6.

11.

3-(3,5-Dimethoxyphenyl)-1,6-naphthyridine-2,7-diamines and related 2-urea derivatives are potent and selective inhibitors of the FGF receptor-1 tyrosine kinase.

Thompson AM, Connolly CJ, Hamby JM, Boushelle S, Hartl BG, Amar AM, Kraker AJ, Driscoll DL, Steinkampf RW, Patmore SJ, Vincent PW, Roberts BJ, Elliott WL, Klohs W, Leopold WR, Showalter HD, Denny WA.

J Med Chem. 2000 Nov 2;43(22):4200-11.

PMID:
11063616
12.

Anticancer efficacy of the irreversible EGFr tyrosine kinase inhibitor PD 0169414 against human tumor xenografts.

Vincent PW, Bridges AJ, Dykes DJ, Fry DW, Leopold WR, Patmore SJ, Roberts BJ, Rose S, Sherwood V, Zhou H, Elliott WL.

Cancer Chemother Pharmacol. 2000;45(3):231-8.

PMID:
10663641
13.

Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo.

Sebolt-Leopold JS, Dudley DT, Herrera R, Van Becelaere K, Wiland A, Gowan RC, Tecle H, Barrett SD, Bridges A, Przybranowski S, Leopold WR, Saltiel AR.

Nat Med. 1999 Jul;5(7):810-6.

PMID:
10395327
14.

Growth inhibition of nasopharyngeal carcinoma cells by EGF receptor tyrosine kinase inhibitors.

Sun Y, Fry DW, Vincent P, Nelson JM, Elliott W, Leopold WR.

Anticancer Res. 1999 Mar-Apr;19(2A):919-24.

PMID:
10368634
15.

Tyrosine kinase inhibitors. 15. 4-(Phenylamino)quinazoline and 4-(phenylamino)pyrido[d]pyrimidine acrylamides as irreversible inhibitors of the ATP binding site of the epidermal growth factor receptor.

Smaill JB, Palmer BD, Rewcastle GW, Denny WA, McNamara DJ, Dobrusin EM, Bridges AJ, Zhou H, Showalter HD, Winters RT, Leopold WR, Fry DW, Nelson JM, Slintak V, Elliot WL, Roberts BJ, Vincent PW, Patmore SJ.

J Med Chem. 1999 May 20;42(10):1803-15.

PMID:
10346932
16.

Regulation of metastasis-related gene expression by p53: a potential clinical implication.

Sun Y, Wicha M, Leopold WR.

Mol Carcinog. 1999 Jan;24(1):25-8.

PMID:
10029407
17.

Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor.

Fry DW, Bridges AJ, Denny WA, Doherty A, Greis KD, Hicks JL, Hook KE, Keller PR, Leopold WR, Loo JA, McNamara DJ, Nelson JM, Sherwood V, Smaill JB, Trumpp-Kallmeyer S, Dobrusin EM.

Proc Natl Acad Sci U S A. 1998 Sep 29;95(20):12022-7.

18.

C-terminal modifications of histidyl-N-benzylglycinamides to give improved inhibition of Ras farnesyltransferase, cellular activity, and anticancer activity in mice.

McNamara DJ, Dobrusin E, Leonard DM, Shuler KR, Kaltenbronn JS, Quin J 3rd, Bur S, Thomas CE, Doherty AM, Scholten JD, Zimmerman KK, Gibbs BS, Gowan RC, Latash MP, Leopold WR, Przybranowski SA, Sebolt-Leopold JS.

J Med Chem. 1997 Oct 10;40(21):3319-22. No abstract available.

PMID:
9341905
19.

Amino-terminal sequence determinants for substrate recognition by platelet-derived growth factor receptor tyrosine kinase.

Chan PM, Keller PR, Connors RW, Leopold WR, Miller WT.

FEBS Lett. 1996 Sep 30;394(2):121-5.

20.

Preclinical antitumor activity of CI-994.

LoRusso PM, Demchik L, Foster B, Knight J, Bissery MC, Polin LM, Leopold WR 3rd, Corbett TH.

Invest New Drugs. 1996;14(4):349-56.

PMID:
9157069
21.

Cellular transport of CI-980.

Hook KE, Przybranowski SA, Leopold WR.

Invest New Drugs. 1996;14(4):341-7.

PMID:
9157068
22.

Inhibition of the epidermal growth factor receptor tyrosine kinase by PD153035 in human A431 tumors in athymic nude mice.

Kunkel MW, Hook KE, Howard CT, Przybranowski S, Roberts BJ, Elliott WL, Leopold WR.

Invest New Drugs. 1996;13(4):295-302.

PMID:
8824347
23.

A specific inhibitor of the epidermal growth factor receptor tyrosine kinase.

Fry DW, Kraker AJ, McMichael A, Ambroso LA, Nelson JM, Leopold WR, Connors RW, Bridges AJ.

Science. 1994 Aug 19;265(5175):1093-5.

PMID:
8066447
25.

Strategies for the discovery of novel tyrosine kinase inhibitors with anticancer activity.

Fry DW, Kraker AJ, Connors RC, Elliott WL, Nelson JM, Showalter HD, Leopold WR.

Anticancer Drug Des. 1994 Aug;9(4):331-51.

PMID:
7916900
26.

Comparative molecular field analysis of in vitro growth inhibition of L1210 and HCT-8 cells by some pyrazoloacridines.

Horwitz JP, Massova I, Wiese TE, Wozniak AJ, Corbett TH, Sebolt-Leopold JS, Capps DB, Leopold WR.

J Med Chem. 1993 Nov 12;36(23):3511-6.

PMID:
8280289
28.

Pharmacologic/pharmacokinetic evaluation of emesis induced by analogs of RSU 1069 and its control by antiemetic agents.

Sebolt-Leopold JS, Vincent PW, Beningo KA, Elliott WL, Leopold WR, Heffner TG, Wiley JN, Stier MA, Suto MJ.

Int J Radiat Oncol Biol Phys. 1992;22(3):549-51.

PMID:
1531213
29.

In vivo and in vitro evaluation of the alkylating agent carmethizole.

Elliott WL, Fry DW, Anderson WK, Nelson JM, Hook KE, Hawkins PA, Leopold WR 3rd.

Cancer Res. 1991 Sep 1;51(17):4581-7.

30.

A new class of analogues of the bifunctional radiosensitizer alpha-(1-aziridinylmethyl)-2-nitro-1H-imidazole-1-ethanol (RSU 1069): the cycloalkylaziridines.

Suto MJ, Stier MA, Werbel LM, Arundel-Suto CM, Leopold WR, Elliott WE, Sebolt-Leopold JS.

J Med Chem. 1991 Aug;34(8):2484-8.

PMID:
1875345
31.

Preclinical antitumor activity of CI-973,[SP-4-3-(R)]-[1,1- cyclobutanedicarboxylato(2-)](2 methyl-1,4-butane-diamine-N,N')platinum.

Kraker AJ, Moore CW, Roberts BJ, Leopold WR, Elliott WL.

Invest New Drugs. 1991 Feb;9(1):1-7.

PMID:
2026477
32.

Antitumor efficacy of PD115934 (NSC 366140) against solid tumors of mice.

LoRusso P, Wozniak AJ, Polin L, Capps D, Leopold WR, Werbel LM, Biernat L, Dan ME, Corbett TH.

Cancer Res. 1990 Aug 15;50(16):4900-5.

33.

Antitumor activity of ethyl 5-amino-1,2-dihydro-2-methyl-3-phenyl-pyrido [3,4-b]pyrazin-7-ylcarbamate, 2-hydroxyethanesulfonate, hydrate (NSC 370147) against selected tumor systems in culture and in mice.

Waud WR, Leopold WR, Elliott WL, Dykes DJ, Laster WR Jr, Temple CG Jr, Harrison SD Jr, Griswold DP Jr.

Cancer Res. 1990 Jun 1;50(11):3239-44.

34.

The pyrazoloacridines: approaches to the development of a carcinoma-selective cytotoxic agent.

Jackson RC, Sebolt JS, Shillis JL, Leopold WR.

Cancer Invest. 1990;8(1):39-47. Review. No abstract available.

PMID:
2190673
35.

Sequence and schedule-dependent synergy of trimetrexate in combination with 5-fluorouracil in vitro and in mice.

Elliott WL, Howard CT, Dykes DJ, Leopold WR.

Cancer Res. 1989 Oct 15;49(20):5586-90.

36.

Biochemical pharmacology and antitumor properties of 4-amino-8-[beta-D-ribofuranosylamino]pyrimido-[5,4-d]pyrimidine.

Jackson RC, Boritzki TJ, Cook PD, Hook KE, Leopold WR, Fry DW.

Adv Enzyme Regul. 1989;28:185-99.

PMID:
2560325
37.

Preclinical studies with trimetrexate: a review of conclusions and unanswered questions.

Jackson RC, Leopold WR, Hamelehle KL, Fry DW.

Semin Oncol. 1988 Apr;15(2 Suppl 2):1-7. Review. No abstract available.

PMID:
2966980
38.

Experimental antitumor activity of the amsacrine analogue CI-921.

Leopold WR 3rd, Corbett TH, Griswold DP Jr, Plowman J, Baguley BC.

J Natl Cancer Inst. 1987 Aug;79(2):343-9.

PMID:
3474465
39.

Anthrapyrazole anticancer agents. Synthesis and structure-activity relationships against murine leukemias.

Showalter HD, Johnson JL, Hoftiezer JM, Turner WR, Werbel LM, Leopold WR, Shillis JL, Jackson RC, Elslager EF.

J Med Chem. 1987 Jan;30(1):121-31.

PMID:
3806589
40.

Biochemical pharmacology and experimental chemotherapy studies with guanine-7-oxide, a novel purine antibiotic.

Jackson RC, Boritzki TJ, Besserer JA, Hamelehle KL, Shillis JL, Leopold WR, Fry DW.

Adv Enzyme Regul. 1987;26:301-16.

PMID:
3673707
41.

Biological effects of acetomycin. I. Activity against tumor cells in vitro and in vivo.

Mamber SW, Mitulski JD, Hamelehle KL, French JC, Hokanson GC, Shillis JL, Leopold WR, Von Hoff DD, Tunac JB.

J Antibiot (Tokyo). 1987 Jan;40(1):73-6.

43.
44.

Design, biochemical pharmacology, electrochemistry and tumour biology of anti-tumour anthrapyrazoles.

Showalter HD, Fry DW, Leopold WR, Lown JW, Plambeck JA, Reszka K.

Anticancer Drug Des. 1986 Apr;1(2):73-85.

PMID:
2453196
45.
46.

In vivo and in vitro anticancer activity of the structurally novel and highly potent antibiotic CI-940 and its hydroxy analog (PD 114,721).

Roberts BJ, Hamelehle KL, Sebolt JS, Leopold WR.

Cancer Chemother Pharmacol. 1986;16(2):95-101.

PMID:
3081269
47.

Cell cycle effects of trimetrexate (CI-898).

Hook KE, Nelson JM, Roberts BJ, Griswold DP, Leopold WR.

Cancer Chemother Pharmacol. 1986;16(2):116-20.

PMID:
2936525
48.

The biochemical pharmacology of (2'-R)-chloropentostatin, a novel inhibitor of adenosine deaminase.

Jackson RC, Leopold WR, Ross DA.

Adv Enzyme Regul. 1986;25:125-39.

PMID:
2433905
49.

Anthrapyrazoles, a new class of intercalating agents with high-level, broad spectrum activity against murine tumors.

Leopold WR, Nelson JM, Plowman J, Jackson RC.

Cancer Res. 1985 Nov;45(11 Pt 1):5532-9.

50.

Collagen-production inhibitors evaluated as antitumor agents.

Klohs WD, Steinkampf RW, Wicha MS, Mertus AE, Tunac JB, Leopold WR.

J Natl Cancer Inst. 1985 Aug;75(2):353-9.

PMID:
3860688

Supplemental Content

Loading ...
Support Center